RJFSA
AMRX icon

Raymond James Financial Services Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28,105
Closed -$202K – 2819
2019
Q2 		$202K Buy
+28,105
New +$287K ﹤0.01% 2534

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Raymond James Financial Services Advisors's AMRX Position: Q3 2019 in Review

Raymond James Financial Services Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 28,105 shares — an estimated $202K sold.

Raymond James Financial Services Advisors first reported a position in AMRX in Q2 2019 and held it in 1 quarter. The position peaked at $202K in Q2 2019. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

  • Raymond James Financial Services Advisors reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 28,105 Amneal Pharmaceuticals shares in Q3 2019, an estimated $202K.
  • Raymond James Financial Services Advisors first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Amneal Pharmaceuticals position peaked at $202K in Q2 2019.
  • 121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2019, filed 7 Nov 2019.